secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-06-29T20:21:05+00:00
Accession:  0001104659-26-078848
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA authorizes IND for Gain Therapeutics' GT-02287, permitting Phase 2 Parkinson's study
--------------------------------------------------------------------------------

- FDA authorized IND for GT-02287, enabling Phase 2 clinical development in Parkinson's disease with or without GBA1 mutation.
- Phase 2a study of oral GT-02287 in early Parkinson's patients planned; sites in U.S., Australia, and Europe.
- Phase 2a initiation expected in Q3 2026; Phase 1a/b were conducted in Australia.
- FDA clearance is a key regulatory milestone for Gain Therapeutics' lead candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926078848/0001104659-26-078848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926078848/tm2619336d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer